Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NPT 2042 Suppression of Photoparoxysmal EEG Response
NCT06525649Phase 1Completed
- Sponsor
- NeuroPro Therapeutics
- Start
- Aug 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of NPT-2042 in photosensitive epilepsy (PSE) (3 arms), sponsored by NeuroPro Therapeutics. Primary endpoint: Change in adjudicated Standard Photosensitivity Range (SPR) at 4 months. Started Aug 2024; status: completed.
02
Drugs
NPT-2042
03
Conditions
photosensitive epilepsy (PSE)
Beyond the preview
Go deeper on NCT06525649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06525649.